S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
pixel
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
pixel
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
pixel
S&P 500   3,811.15
DOW   30,932.37
QQQ   314.14
pixel
pixel
Log in
NASDAQ:GNPX

Genprex Competitors

$5.16
-0.15 (-2.82 %)
(As of 02/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$5.01
Now: $5.16
$5.50
50-Day Range
$3.66
MA: $5.14
$7.67
52-Week Range
$1.49
Now: $5.16
$7.72
Volume834,702 shs
Average Volume1.82 million shs
Market Capitalization$223.31 million
P/E RatioN/A
Dividend YieldN/A
Beta-0.57

Competitors

Genprex (NASDAQ:GNPX) Vs. PRTA, PAHC, LXRX, EPIX, RDUS, and FPRX

Should you be buying GNPX stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Genprex, including Prothena (PRTA), Phibro Animal Health (PAHC), Lexicon Pharmaceuticals (LXRX), ESSA Pharma (EPIX), Radius Health (RDUS), and Five Prime Therapeutics (FPRX).

Prothena (NASDAQ:PRTA) and Genprex (NASDAQ:GNPX) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, dividends, valuation and profitability.

Volatility & Risk

Prothena has a beta of 1.71, indicating that its stock price is 71% more volatile than the S&P 500. Comparatively, Genprex has a beta of -0.57, indicating that its stock price is 157% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Prothena and Genprex, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Prothena00703.00
Genprex00303.00

Prothena currently has a consensus target price of $28.2857, suggesting a potential upside of 26.73%. Genprex has a consensus target price of $6.00, suggesting a potential upside of 16.28%. Given Prothena's higher probable upside, equities research analysts plainly believe Prothena is more favorable than Genprex.

Valuation & Earnings

This table compares Prothena and Genprex's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Prothena$810,000.001,100.05$-77,680,000.00($1.95)-11.45
GenprexN/AN/A$-10,650,000.00($0.67)-7.70

Genprex has lower revenue, but higher earnings than Prothena. Prothena is trading at a lower price-to-earnings ratio than Genprex, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

90.2% of Prothena shares are owned by institutional investors. Comparatively, 12.5% of Genprex shares are owned by institutional investors. 30.4% of Prothena shares are owned by insiders. Comparatively, 13.1% of Genprex shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Prothena and Genprex's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Prothena-13,615.75%-41.97%-26.26%
GenprexN/A-81.49%-79.54%

Summary

Prothena beats Genprex on 8 of the 12 factors compared between the two stocks.

Genprex (NASDAQ:GNPX) and Phibro Animal Health (NASDAQ:PAHC) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings.

Risk & Volatility

Genprex has a beta of -0.57, meaning that its stock price is 157% less volatile than the S&P 500. Comparatively, Phibro Animal Health has a beta of 0.46, meaning that its stock price is 54% less volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and price targets for Genprex and Phibro Animal Health, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Genprex00303.00
Phibro Animal Health11102.00

Genprex currently has a consensus target price of $6.00, suggesting a potential upside of 16.28%. Phibro Animal Health has a consensus target price of $21.50, suggesting a potential downside of 0.32%. Given Genprex's stronger consensus rating and higher probable upside, analysts clearly believe Genprex is more favorable than Phibro Animal Health.

Valuation and Earnings

This table compares Genprex and Phibro Animal Health's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GenprexN/AN/A$-10,650,000.00($0.67)-7.70
Phibro Animal Health$800.40 million1.09$33.55 million$1.0819.97

Phibro Animal Health has higher revenue and earnings than Genprex. Genprex is trading at a lower price-to-earnings ratio than Phibro Animal Health, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

12.5% of Genprex shares are owned by institutional investors. Comparatively, 50.3% of Phibro Animal Health shares are owned by institutional investors. 13.1% of Genprex shares are owned by company insiders. Comparatively, 50.1% of Phibro Animal Health shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Genprex and Phibro Animal Health's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
GenprexN/A-81.49%-79.54%
Phibro Animal Health5.37%23.70%5.99%

Summary

Phibro Animal Health beats Genprex on 10 of the 13 factors compared between the two stocks.

Genprex (NASDAQ:GNPX) and Lexicon Pharmaceuticals (NASDAQ:LXRX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings.

Risk & Volatility

Genprex has a beta of -0.57, meaning that its stock price is 157% less volatile than the S&P 500. Comparatively, Lexicon Pharmaceuticals has a beta of 2.09, meaning that its stock price is 109% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and price targets for Genprex and Lexicon Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Genprex00303.00
Lexicon Pharmaceuticals06202.25

Genprex currently has a consensus target price of $6.00, suggesting a potential upside of 16.28%. Lexicon Pharmaceuticals has a consensus target price of $9.40, suggesting a potential upside of 30.74%. Given Lexicon Pharmaceuticals' higher probable upside, analysts clearly believe Lexicon Pharmaceuticals is more favorable than Genprex.

Valuation and Earnings

This table compares Genprex and Lexicon Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GenprexN/AN/A$-10,650,000.00($0.67)-7.70
Lexicon Pharmaceuticals$322.07 million2.71$130.13 million$1.355.33

Lexicon Pharmaceuticals has higher revenue and earnings than Genprex. Genprex is trading at a lower price-to-earnings ratio than Lexicon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

12.5% of Genprex shares are owned by institutional investors. Comparatively, 84.6% of Lexicon Pharmaceuticals shares are owned by institutional investors. 13.1% of Genprex shares are owned by company insiders. Comparatively, 6.4% of Lexicon Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Genprex and Lexicon Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
GenprexN/A-81.49%-79.54%
Lexicon Pharmaceuticals-320.44%-164.96%-31.83%

Summary

Lexicon Pharmaceuticals beats Genprex on 8 of the 13 factors compared between the two stocks.

Genprex (NASDAQ:GNPX) and ESSA Pharma (NASDAQ:EPIX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings.

Risk & Volatility

Genprex has a beta of -0.57, meaning that its stock price is 157% less volatile than the S&P 500. Comparatively, ESSA Pharma has a beta of 1.96, meaning that its stock price is 96% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and price targets for Genprex and ESSA Pharma, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Genprex00303.00
ESSA Pharma00403.00

Genprex currently has a consensus target price of $6.00, suggesting a potential upside of 16.28%. ESSA Pharma has a consensus target price of $23.50, suggesting a potential downside of 13.25%. Given Genprex's higher probable upside, analysts clearly believe Genprex is more favorable than ESSA Pharma.

Valuation and Earnings

This table compares Genprex and ESSA Pharma's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GenprexN/AN/A$-10,650,000.00($0.67)-7.70
ESSA PharmaN/AN/A$-23,440,000.00($1.04)-26.05

ESSA Pharma is trading at a lower price-to-earnings ratio than Genprex, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

12.5% of Genprex shares are owned by institutional investors. Comparatively, 63.4% of ESSA Pharma shares are owned by institutional investors. 13.1% of Genprex shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Genprex and ESSA Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
GenprexN/A-81.49%-79.54%
ESSA PharmaN/A-46.31%-45.08%

Genprex (NASDAQ:GNPX) and Radius Health (NASDAQ:RDUS) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings.

Risk & Volatility

Genprex has a beta of -0.57, meaning that its stock price is 157% less volatile than the S&P 500. Comparatively, Radius Health has a beta of 1.18, meaning that its stock price is 18% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and price targets for Genprex and Radius Health, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Genprex00303.00
Radius Health06202.25

Genprex currently has a consensus target price of $6.00, suggesting a potential upside of 16.28%. Radius Health has a consensus target price of $23.3333, suggesting a potential upside of 25.38%. Given Radius Health's higher probable upside, analysts clearly believe Radius Health is more favorable than Genprex.

Valuation and Earnings

This table compares Genprex and Radius Health's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GenprexN/AN/A$-10,650,000.00($0.67)-7.70
Radius Health$173.32 million5.00$-132,990,000.00($2.89)-6.44

Genprex has higher earnings, but lower revenue than Radius Health. Genprex is trading at a lower price-to-earnings ratio than Radius Health, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

12.5% of Genprex shares are owned by institutional investors. 13.1% of Genprex shares are owned by company insiders. Comparatively, 2.9% of Radius Health shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Genprex and Radius Health's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
GenprexN/A-81.49%-79.54%
Radius Health-48.61%N/A-56.85%

Summary

Genprex beats Radius Health on 7 of the 13 factors compared between the two stocks.

Genprex (NASDAQ:GNPX) and Five Prime Therapeutics (NASDAQ:FPRX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, risk, profitability, dividends, valuation, institutional ownership and earnings.

Risk & Volatility

Genprex has a beta of -0.57, meaning that its stock price is 157% less volatile than the S&P 500. Comparatively, Five Prime Therapeutics has a beta of 4.4, meaning that its stock price is 340% more volatile than the S&P 500.

Analyst Recommendations

This is a summary of current ratings and price targets for Genprex and Five Prime Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Genprex00303.00
Five Prime Therapeutics01602.86

Genprex currently has a consensus target price of $6.00, suggesting a potential upside of 16.28%. Five Prime Therapeutics has a consensus target price of $25.00, suggesting a potential upside of 12.46%. Given Genprex's stronger consensus rating and higher probable upside, analysts clearly believe Genprex is more favorable than Five Prime Therapeutics.

Valuation and Earnings

This table compares Genprex and Five Prime Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GenprexN/AN/A$-10,650,000.00($0.67)-7.70
Five Prime Therapeutics$14.87 million56.87$-137,200,000.00($3.92)-5.67

Genprex has higher earnings, but lower revenue than Five Prime Therapeutics. Genprex is trading at a lower price-to-earnings ratio than Five Prime Therapeutics, indicating that it is currently the more affordable of the two stocks.

Insider and Institutional Ownership

12.5% of Genprex shares are owned by institutional investors. Comparatively, 67.3% of Five Prime Therapeutics shares are owned by institutional investors. 13.1% of Genprex shares are owned by company insiders. Comparatively, 6.4% of Five Prime Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Profitability

This table compares Genprex and Five Prime Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
GenprexN/A-81.49%-79.54%
Five Prime Therapeutics-554.71%-75.84%-49.08%

Summary

Five Prime Therapeutics beats Genprex on 7 of the 13 factors compared between the two stocks.


Genprex Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Prothena logo
PRTA
Prothena
2.1$22.32-1.3%$891.04 million$810,000.00-8.72Analyst Upgrade
Insider Buying
Gap Down
Phibro Animal Health logo
PAHC
Phibro Animal Health
1.8$21.57-3.3%$872.57 million$800.40 million20.35High Trading Volume
Gap Up
Lexicon Pharmaceuticals logo
LXRX
Lexicon Pharmaceuticals
1.8$7.19-4.0%$871.31 million$322.07 million-6.85News Coverage
ESSA Pharma logo
EPIX
ESSA Pharma
1.1$27.09-6.1%$868.61 millionN/A-25.08Analyst Report
Increase in Short Interest
News Coverage
Gap Up
Radius Health logo
RDUS
Radius Health
1.3$18.61-2.3%$866.24 million$173.32 million-7.63Earnings Announcement
Analyst Report
News Coverage
Gap Down
Five Prime Therapeutics logo
FPRX
Five Prime Therapeutics
1.5$22.23-3.8%$845.59 million$14.87 million-8.29News Coverage
Gap Down
G1 Therapeutics logo
GTHX
G1 Therapeutics
1.5$22.10-1.2%$840.82 millionN/A-7.62Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Dyne Therapeutics logo
DYN
Dyne Therapeutics
1.6$18.47-4.7%$839.41 millionN/A0.00Upcoming Earnings
Gap Down
Amphastar Pharmaceuticals logo
AMPH
Amphastar Pharmaceuticals
1.7$17.53-2.1%$832.75 million$322.36 million125.21High Trading Volume
Collegium Pharmaceutical logo
COLL
Collegium Pharmaceutical
1.4$23.59-10.3%$815.79 million$296.70 million48.14Earnings Announcement
Analyst Downgrade
News Coverage
Gap Down
VBI Vaccines logo
VBIV
VBI Vaccines
1.5$3.37-2.7%$815.72 million$2.22 million-19.82Upcoming Earnings
Analyst Report
Analyst Revision
News Coverage
Odonate Therapeutics logo
ODT
Odonate Therapeutics
2.1$21.05-3.1%$812.61 millionN/A-5.37Earnings Announcement
Analyst Revision
News Coverage
Gap Up
Kadmon logo
KDMN
Kadmon
2.0$4.59-0.2%$787.25 million$5.09 million-7.65Upcoming Earnings
News Coverage
AnaptysBio logo
ANAB
AnaptysBio
1.1$28.70-9.5%$784.89 million$8 million-10.59Earnings Announcement
Insider Buying
Analyst Revision
News Coverage
Gap Up
Esperion Therapeutics logo
ESPR
Esperion Therapeutics
1.2$27.39-1.1%$763.55 million$148.36 million-7.11Earnings Announcement
Analyst Report
Analyst Revision
News Coverage
Provention Bio logo
PRVB
Provention Bio
1.4$12.72-0.9%$718.53 millionN/A-8.54Earnings Announcement
Analyst Report
News Coverage
Intercept Pharmaceuticals logo
ICPT
Intercept Pharmaceuticals
1.9$21.66-6.4%$714.61 million$252 million-2.21Earnings Announcement
Analyst Downgrade
High Trading Volume
Analyst Revision
News Coverage
Gap Down
Gossamer Bio logo
GOSS
Gossamer Bio
1.7$9.40-4.1%$713.72 millionN/A-2.64Earnings Announcement
Analyst Revision
News Coverage
Gap Down
Merus logo
MRUS
Merus
1.4$22.50-8.9%$711.07 million$31.13 million-7.33Gap Up
OrganiGram logo
OGI
OrganiGram
1.2$3.03-1.7%$703.78 million$64.61 million-4.46Unusual Options Activity
Rigel Pharmaceuticals logo
RIGL
Rigel Pharmaceuticals
1.6$4.15-0.2%$701.27 million$59.29 million-27.66Upcoming Earnings
Analyst Report
News Coverage
Gap Down
Akouos logo
AKUS
Akouos
1.7$20.37-2.1%$700.38 millionN/A0.00Upcoming Earnings
High Trading Volume
News Coverage
Gap Down
Chinook Therapeutics logo
KDNY
Chinook Therapeutics
1.6$16.54-1.7%$697.29 million$17.26 million-4.59
Calliditas Therapeutics AB (publ) logo
CALT
Calliditas Therapeutics AB (publ)
1.4$28.07-2.7%$672.81 million$19.56 million-20.19Analyst Report
Decrease in Short Interest
News Coverage
Gap Down
Albireo Pharma logo
ALBO
Albireo Pharma
1.5$34.86-0.6%$665.02 million$9.64 million-5.68Earnings Announcement
Analyst Revision
News Coverage
Xenon Pharmaceuticals logo
XENE
Xenon Pharmaceuticals
1.4$18.68-3.0%$653.93 million$6.83 million-19.26Upcoming Earnings
Analyst Report
BCEL
Atreca
1.7$17.35-2.3%$636.87 millionN/A-6.15Earnings Announcement
News Coverage
Gap Down
Chimerix logo
CMRX
Chimerix
1.3$9.81-8.8%$614.44 million$12.52 million-17.21Earnings Announcement
News Coverage
Gap Down
KalVista Pharmaceuticals logo
KALV
KalVista Pharmaceuticals
1.8$32.87-1.1%$589.75 million$12.69 million-15.80Analyst Report
Insider Selling
Foghorn Therapeutics logo
FHTX
Foghorn Therapeutics
1.5$16.46-1.0%$589.50 millionN/A0.00Upcoming Earnings
Ardelyx logo
ARDX
Ardelyx
1.9$6.45-0.3%$582.10 million$5.28 million-6.39Upcoming Earnings
News Coverage
Gap Down
Eagle Pharmaceuticals logo
EGRX
Eagle Pharmaceuticals
1.5$44.50-2.9%$579.84 million$195.89 million127.15Upcoming Earnings
Gap Down
Evelo Biosciences logo
EVLO
Evelo Biosciences
1.9$12.17-12.2%$577.71 millionN/A-4.89Upcoming Earnings
Gap Down
IVA
Inventiva
0.0$15.00-3.6%$575.90 millionN/A0.00High Trading Volume
Gap Down
Summit Therapeutics logo
SMMT
Summit Therapeutics
0.6$6.77-3.0%$559.03 million$56.50 million0.00Decrease in Short Interest
Gap Down
XBiotech logo
XBIT
XBiotech
1.2$19.00-0.3%$555.96 millionN/A1.32News Coverage
Geron logo
GERN
Geron
1.4$1.79-1.1%$555.75 million$460,000.00-5.11
IDYA
IDEAYA Biosciences
1.3$19.07-4.7%$554.37 millionN/A-10.14Gap Up
Applied Therapeutics logo
APLT
Applied Therapeutics
1.8$21.72-5.6%$553.73 millionN/A-4.56Insider Buying
News Coverage
Gap Down
IVERIC bio logo
ISEE
IVERIC bio
1.5$6.14-2.1%$549.95 millionN/A-4.87Upcoming Earnings
News Coverage
Molecular Templates logo
MTEM
Molecular Templates
2.0$10.90-1.1%$544.61 million$22.27 million-5.34Analyst Upgrade
Insider Buying
News Coverage
Gap Down
AC Immune logo
ACIU
AC Immune
1.3$7.59-0.9%$544.51 million$111.75 million-8.43
Flexion Therapeutics logo
FLXN
Flexion Therapeutics
1.4$11.02-0.5%$543.45 million$72.96 million-3.57
Relmada Therapeutics logo
RLMD
Relmada Therapeutics
1.1$33.34-1.5%$541.51 millionN/A-15.44Gap Down
Bicycle Therapeutics logo
BCYC
Bicycle Therapeutics
1.3$25.27-1.3%$538.38 million$13.80 million-12.21
Urovant Sciences logo
UROV
Urovant Sciences
0.7$16.17-0.1%$529.45 millionN/A-3.14
Clovis Oncology logo
CLVS
Clovis Oncology
1.4$5.99-0.8%$529.03 million$143.01 million-1.14Earnings Announcement
Analyst Report
Analyst Revision
Altimmune logo
ALT
Altimmune
1.9$15.94-7.9%$527.15 million$5.80 million-8.01Earnings Announcement
Analyst Revision
News Coverage
Gap Down
Amryt Pharma logo
AMYT
Amryt Pharma
1.4$14.74-2.2%$527.10 million$58.12 million-17.14Increase in Short Interest
News Coverage
BeyondSpring logo
BYSI
BeyondSpring
1.2$12.98-0.6%$508.06 millionN/A-6.36News Coverage
This page was last updated on 2/28/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.